Success Rate of Discontinuation of Nasal High Flow Cannula at 4 LPM Compared to 2 LPM in Late Preterm and Term Neonates with Respiratory Distress

Success Rate of Discontinuation of High Flow Nasal Cannula at 4 LPM Compared to 2 LPM in Late Preterm and Term Neonates with Respiratory Distress

Status

Active, not recruiting

Phases

Phase 1

Study type

Interventional

Source

TCTR

Registry ID

TCTR20220613009

Enrollment

Registered

2022-06-13

Start date

2021-10-25

Completion date

Unknown

Last updated

2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Late preterm and term infants admitted in the neonatal unit at Queen Sirikit National Institute of Child Health (QSNICH) receiving respiratory support via HFNC for any indication High flow nasal cannula, newborn, discontinuation, respiratory distress

Interventions

Weaning from HFNC therapy was performed when the infant&#039

s respiratory condition was stable for 12 hours if respiratory rate lower than 60 bpm, no significant chest retraction, no apnea and FiO2 requirement lower than 0.3. The gas flow was decreased in dec

s body weight was more than 2,500 grams and every 4-12 hours if infant&#039

s body weight was below 2,500 grams.HFNC therapy was discontinued when the predefined flow was 4 LPM. After ceasing HFNC therapy, patients were followed for 48 hours. If the infants met failure criter

s body weight was below 2,500 grams.HFNC therapy was discontinued when the predefined flow was 2 LPM. After ceasing HFNC therapy, patients were followed for 48 hours. If the infants met failure criter

Experimental Device,Experimental Device

discontinuation of HFNC at predefined flow 4 LPM,discontinuation of HFNC at predefined flow 2 LPM

Eligibility

Sex/Gender

All

Age

1 Days to 28 Days

Inclusion criteria

Inclusion criteria: Late preterm and term infant admitted in the neonatal unit at Queen Sirikit National Institute of Child Health (QSNICH) receiving respiratory support via HFNC for any indication were eligible for enrollment

Exclusion criteria

Exclusion criteria: Excluded from the study were infants with major congenital abnormalities, chromosomal abnormalities, or infants for whom the attending physician judged inclusion to be inappropriate.

Design outcomes

Primary

Measure	Time frame
the success rate of discontinue HFNC therapy at predefined flow 2 LPM versus predefined flow 4 LPM. until discharge success rate	—

Secondary

Measure	Time frame
duration of HFNC from initial intervention duration of hospital stay and incidence of air leak, apnea, and nasal trauma until discharge number as percent	—

Countries

Thailand

Contacts

Public Contactnattakarn sookhanaphibarn

Queen Sirikit National Institute of Child Health

nsookhanaphibarn@gmail.com0892257329

Outcome results

None listed

Source: TCTR (via WHO ICTRP) · Data processed: Aug 9, 2026